Results 11 to 20 of about 82,322 (223)

Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence. [PDF]

Cancer Innov
Statins, particularly simvastatin, demonstrate potential as adjuvant agents in breast cancer treatment by disrupting tumour cell signalling and survival pathways. This review highlights emerging evidence supporting their repurposing for improved outcomes, especially in aggressive breast cancer subtypes.
Alim R, Akalanka HMK.
europepmc   +2 more sources

Multicomponent crystals: Solubility enhancement of simvastatin using arginine and glycine coformers [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Simvastatin can be modified by the formation of multicomponent crystals to increase its solubility. Aims: To compare the solubility of multicomponent simvastatin crystals to pure simvastatin. Methods: The in silico study of simvastatin and
Iyan Sopyan, Karyn Elizabeth, Sandra Megantara, Silmy Kaffah   +3 more
doaj   +1 more source

Simvastatin inhibits TLR8 signaling in primary human monocytes and spontaneous TNF production from rheumatoid synovial membrane cultures [PDF]

, 2015
Simvastatin has been shown to have anti-inflammatory effects that are independent of its serum cholesterol lowering action, but the mechanisms by which these anti-inflammatory effects are mediated have not been elucidated.
A Gierut, A Hilgendorff, AA Ajibade, BI Gavrila, BP Leung, C Arnaud, C Guiducci, C Guijarro, E Munro, EH Choy, FL Zhang, FM Brennan, FM Brennan, FX Zhang, G Falgarone, H Kanda, H Kanda, H Lin, H Methe, H Okamoto, H Radner, H Wesche, H Xu, I Zelvyte, J Qin, Jason Ferdjani, K Chaabo, KA Fitzgerald, KA Fitzgerald, KH Costenbader, KI Paraskevas, L Liu, LA O’Neill, Lisa Mullen, LM Mullen, M Khoury, M Ortego, M Yamamoto, M Yoshida, MA Gonzalez-Gay, QQ Huang, S Alzabin, S Doornum Van, Sandra Sacre, SL Chinault, SM Sacre, T Mosmann, TT Tang, U Schonbeck   +48 more
core   +1 more source

Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial : study protocol for a randomized controlled trial [PDF]

, 2012
Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening respiratory failure requiring mechanical ventilation and multiple organ failure.
A Mercat, AM Cheung, C Brun-Buisson, C Rossi, Cecilia M O’Kane, Christine McNally, Daniel F McAuley, DJ Kor, Excellence NIfHaC, F Gao Smith, Gavin D Perkins, GD Rubenfeld, GR Bernard, Grainne Crealey, Irish Critical Care Trials Group, John G Laffey, KF Schulz, LA Curtis, Lynn Murphy, M Shyamsundar, MA Matthay, Mark Cross, Michael Stevenson, MS Herridge, RG Brower, S Harvey, SE Erickson, T Craig, The ARDS Network investigators, The EuroQol Group, TR Craig, TW Felton   +31 more
core   +1 more source

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]

, 2017
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin, Amento, Edward P, Kong, Raymond, Liu, David, Lundry, Jason, Madasamy, Shanmugavel, Robinson, J Paul, Wu, Alan HB   +7 more
core   +1 more source

Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension

Clinical and Experimental Hypertension, 2018
Background: Recent research has shown that statins improve pulmonary arterial hypertension (PAH), but their mechanisms of action are not fully understood.
Wei-Hua Liu, Xiao-Hong Xu, Qin Luo, Hong-Liang Zhang, Yong Wang, Qun-Ying Xi, Zhi-Hui Zhao, Zhi-Hong Liu   +7 more
doaj   +1 more source

Enhancement of Autophagy by Simvastatin through Inhibition of Rac1-mTOR Signaling Pathway in Coronary Arterial Myocytes

Cellular Physiology and Biochemistry, 2013
Background/Aims: In addition to their action of lowering blood cholesterol levels, statins modulate biological characteristics and functions of arterial myocytes such as viability, proliferation, apoptosis, survival and contraction.
Yu-Miao Wei, Xiang Li, Ming Xu, Justine M. Abais, Yang Chen, Christopher R. Riebling, Krishna M. Boini, Pin-Lan Li, Yang Zhang   +8 more
doaj   +1 more source

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Pharmaceuticals, 2023
Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung, Jong-Min Kim, Jin-Woo Park, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Effects of simvastatin on apolipoprotein M in vivo and in vitro

Lipids in Health and Disease, 2011
Objective To investigate effects of lipid lowering drug, simvastatin, on apolipoprotein M expression in the hyperlipidemic mice and in hepatic cell line, HepG2 cells. Methods Swiss male mice were randomly divided into the high fat group and control group,
Nilsson-Ehle Peter, Berggren-Söderlund Maria, Wei Jiang, Luo Guanghua, Mao Shubing, Zhang Xiaoying, Xu Ning   +6 more
doaj   +1 more source

Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. [PDF]

PLoS ONE, 2013
Renal cell carcinoma (RCC) is the most lethal type of genitourinary cancer due to its occult onset and resistance to chemotherapy and radiation. Recently, accumulating evidence has suggested stains, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A ...
Zhiqing Fang, Yueqing Tang, Juanjuan Fang, Zunlin Zhou, Zhaoquan Xing, Zhaoxin Guo, Xiaoyu Guo, Weichang Wang, Wei Jiao, Zhonghua Xu, Zhaoxu Liu   +10 more
doaj   +1 more source